that is used as an effective immunosuppressant for kidney transplantation.
2) It inhibits inosine monophosphate dehydrogenase (IMPDH) and thus exerts pleiotropic effects on both immune and non-immune cells. [3] [4] [5] We have previously found that MPA from a fermentation broth of Penicillium sp. inhibited adipocyte differentiation of 3T3-L1 cells. Although this effect was attributed to the inhibition of IMPDH, another molecular target of 1 was found to be PPAR, and 1 was a latent agonist of this nuclear hormone receptor. 6) MPA has potential anti-cancer activity, and numerous studies have appeared in the literature. [7] [8] [9] [10] Due to its apoptotic properties, 1 has entered phase I clinical trials in advanced multiple myeloma patients. 11, 12) Dynamic histone acetylation and deacetylation exhibit a critical regulatory function on gene expression through an effect on nucleosome conformation. 13) Interestingly, histone deacetylase (HDAC) inhibitors specifically induce the expression level of such anticancer genes as p21, TRAIL and FasL, DR5 and FAS in leukemia cells and not in normal cells. [14] [15] [16] The outstanding selective toxicity of such HDAC inhibitors as suberoylanilide hydroxamic acid (SAHA), 17) 4-(acetylamino)-N-(2-amiophenyl) benzamide (CI-994) 18, 19) and cyclo[(2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl], cyclic (3!5)-3-disulfide (FK-228) 20) might provide effective anticancer drugs in the near future. Most of such HDAC inhibitors, including trichostatin A (TSA), 21) show non-specific inhibitory activity against HDACs from both classes I and II.
Isotype-specific HDAC inhibitors are valuable in respect to their role as a chemical probe of the biological functions of HDACs and as therapeutic agents targeting the activities of these isotypes. So far, only a few HDAC isotype-specific inhibitors have been developed such as tubacin toward -tubulin deacetylation and histacin toward histone deacetylation. 22) The crystal structure of a bacterial HDAC homolog bound to TSA allows for an analysis of the structural properties of HDAC * Part of this work was presented at the International Chemical Congress of Pacific Basin Societies: The paper was entitled ''Mycophenolic acid and its analogs, development of ligands of PPARs and HDAC inhibitors'' by Ubukata et al., Pacifichem, December 17, Hawaii (2005) . DIB and DHK contributed equally to this work. 23) In view of these structure features, MPA (1), which possesses a cap, a linker and a weak metalbinding site, seems to be a latent HDAC inhibitor, and its hydroxamic acid analog, MPHA (2), having an efficient metal binding site, could be a new HDAC inhibitor (Fig. 1) . The presence of a hydroxamic acid function in the HDAC molecule is of importance since this group coordinates the zinc cation in a bidentate fashion and hydrogen bonds with some of the active site residues of HDAC. The cap group possibly mimics the amino acids adjacent to the acetylated lysine residue in histone and tubulin. Differences in the cap between TSA or SAHA and MPHA might lead to differences in the specificity of the inhibitor. Thus, we introduced the design and synthesis of MPHA (2), 7-O-Ac MPHA (3), and 7-O-lauroyl (7-O-L MPHA, 4) and the evaluation of their HDAC activities at the cellular level at an international academic meeting in 2005. 24) Pankiewicz et al. have recently reported the synthesis of 2 as well as its inhibitory activity against HDAC and IMPDH. 25) We report here the design, synthesis and biological evaluation of the new HDAC inhibitors, 2, 3 and 4, having a mycophenolic-acid structure as pharmacophores in detail (Fig. 1 ).
Materials and Methods
Chemistry. Mycophenolic acid (MPA) was isolated from a culture broth of Penicillium sp. BAUA 2775 (presented by Kaken Pharmaceutical Co.), or purchased from Sigma (Saint Louis, MO, USA). All chemicals were purchased in the highest purity available and were used without further purification. Thin-layer and column chromatography (CC) were respectively performed with Merck silica gel 60 F 254 and Kanto Chemical Co. silica gel 60 N (spherical, neutral). NMR spectra were recorded on a Bruker AMX-500 spectrometer. Chemical shifts are reported in ppm (-scale), using TMS as the internal standard. Coupling constants (J) are given in Hz. MS spectra were measured with JMS-SX102A equipment, using EI and FAB techniques. The NMR and MS data were obtained at the GC-MS & NMR Laboratory, Faculty of Agriculture, Hokkaido University, Sapporo, Japan.
(E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenohydroxamic acid (2) . Ethylchloroformate (59.6 ml, 0.63 mmol) and Et 3 N (93 ml, 0.66 mmol) were added to a solution of 1 (100.0 mg, 0.31 mmol) in THF (2 ml) at 0 C, and the mixture was stirred for 45 min. The solid was filtered off, and the filtrate was added to a freshly prepared solution of hydroxylamine hydrochloride (110.0 mg, 1.58 mmol) and KOH (88.6 mg, 1.58 mmol) in MeOH (0.5 ml). (E)-6-(1,3-Dihydro-4-acetoxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenohydroxamic acid (3) . Ethylchloroformate (9.0 ml, 0.09 mmol) and Et 3 N (13 ml, 0.09 mmol) were added to a solution of acetylated MPA (6) (17.0 mg, 0.05 mmol) in THF (2 ml) at 0 C, and the mixture was stirred for 45 min. To this solution, hydroxylamine hydrochloride (26.0 mg, 0.38 mmol) and Et 3 N (52 ml, 0.38 mmol) were then added. After 12 h of stirring, the reaction mixture was evaporated, washed with 2 M HCl, dried over Na 2 SO 4 and evaporated to obtain pure 3 (16.5 mg, 93% (E)-6-(1,3-Dihydro-4-dodecanoyloxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid (7) . A solution of lauric acid anhydride (11 mg, 0.03 mmol) in pyridine was added to a solution of MPA, 1 (20 mg, 0.06 mmol) and 4-DMAP in pyridine. The reaction mixture was stirred at room temperature for 5 d. Water was then added, and the product was extracted with (E)-6-(1,3-Dihydro-4-dodecanoyloxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenohydroxamic acid (4). Ethylchloroformate (6.0 ml, 0.06 mmol) and Et 3 N (10 ml, 0.07 mmol) were added to a solution of 7-O-lauroyl MPA (7; 12.6 mg, 0.03 mmol) in THF (2 ml) at 0 C, and the mixture was stirred for 45 min. To this solution, hydroxylamine hydrochloride (16.7 mg, 0.24 mmol) and Et 3 N (35 ml, 0.24 mmol) were then added. After 10 h of stirring, the reaction mixture was evaporated, washed with 2 M HCl, dried over Na 2 SO 4 and evaporated. 7-O-Lauroyl MPHA (4) (E)-6-(1,3-Dihydro-4,6-dimethoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenohydroxamic acid (11) . Ethylchloroformate (12.0 ml, 0.14 mmol) and Et 3 N (21 ml, 0.15 mmol) were added to a solution of compound 8 (23.0 mg, 0.07 mmol) in dry THF (2 ml) at 0 C, and the mixture was stirred for 45 min. To this solution, hydroxylamine hydrochloride (39.0 mg, 0.56 mmol) was then added. After 10 h of stirring, the reaction mixture was evaporated, washed with 2 M HCl, dried over Na 2 SO 4 and evaporated. The residue was purified by PTLC (CHCl 3 /EtOAc, 1/1) to give a white solid (21.7 mg, 90% (E)-6-(1,3-Dihydro-4-(2-methoxyethoxy)methoxy-6-hydroxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenohydroxamic acid (12) . A solution of 5 M KOH in MeOH (2 ml) was added dropwise while stirring to a mixture containing compound 9 (46.4 mg, 0.11 mmol) dissolved in THF (1.5 ml) and hydroxylamine hydrochloride (61 mg, 0.88 mmol) dissolved in MeOH (2 ml). After stirring at room temperature for 5 d, the solvent was evaporated. The solid residue was acidified with AcOH/H 2 O (1/1,10 ml) and extracted with EtOAc. Concentration of the combined organic phase gave a solid which was purified by PTLC (CHCl 3 /MeOH, 19/1) to give 12 as a yellow solid (39.7 mg, 85% (E)-6-(1,3-Dihydro-4-(4-methylbenzenesulfonoyloxy)-6-hydroxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenohydroxamic acid (13) . Ethylchloroformate (4 ml, 0.04 mmol) and Et 3 N (87 ml, 0.05 mmol) were added to a solution of compound 10 (7.7 mg, 0.02 mmol) in dry THF (1 ml) at 0 C, and the mixture was stirred for 45 min. To this solution, hydroxylamine hydrochloride (11.0 mg, 0.16 mmol) and Et 3 N (22 ml, 0.16 mmol) were then added. After 10 h of stirring, the reaction mixture was evaporated, washed with 2 M HCl, dried over Na 2 SO 4 and evaporated. The residue was purified by PTLC (CHCl 3 /EtOAc, 1/1) to give 13 as a white solid (4.5 mg, 56% Cell culture. Human cervical carcinoma cells (HeLa) were maintained in a DMEM medium containing 10% (v/v) heat-inactivated fetal bovine serum (FBS), 2 g/l of sodium bicarbonate, 100 mg/ml of streptomycin, and 100 U/ml of penicillin G at 37 C under 5% CO 2 . Erythroleukemia cell line K562 was maintained in an RPMI-1640 medium containing 10% (v/v) heat-inactivated fetal bovine serum (FBS), 2 g/l of sodium bicarbonate, 100 mg/ml of streptomycin, and 20 U/ml of penicillin G at 37 C under 5% CO 2 . Proliferation assay. HeLa cells were plated on a 96-well plate (3 Â 10 3 cells per well), and incubated under the conditions already described. After 24 h, the cells were treated with chemicals dissolved in DMSO at various concentrations for 72 h. The morphology was then observed by optical microscopy at a Â100 magnification (Olympus Optical, Melville, NY, USA). Cellular proliferation was then measured by an MTT assay. The IC 50 values for cell proliferation were determined by plotting the absorbance versus drug concentration. The compound concentration corresponding to 50% of the control is defined as the IC 50 value for the cell proliferation assay.
In vitro HDAC enzyme assay. The nuclear fraction of HeLa cells was prepared for the in vitro enzyme assay. Cultured HeLa cells in a 10-mm dish were treated with lysis buffer (50 mM KCl, 25 mM HEPES (pH 7.9), and 0.5% Nonidet P-40 (NP-40; octyl phenoxylpolyethoxylethanol) and a protease inhibitor cocktail (complete Mini, Roche, Germany)), and centrifuged at 3,000 rpm for 30 s. The pellet was obtained and washed with a buffer without NP-40. After washing, it was treated with a lysis buffer (50 mM Tris at pH 8.0, 150 mM NaCl, 10% glycerol, 0.5% Triton X-100, and a protease inhibitor cocktail) and then centrifuged at 13,000 rpm for 10 min. The protein concentration was measured by a Bradford assay. Using approximately 10 mg of the prepared nuclear lysate, the reaction was performed with the commercially available AK-500 kit from Biomol (Butler Pike, PA, USA), according to the manufacturer's instructions. A deacetylated substrate was detected by fluorescence with an FL600 Microplate Reader (Bio-Tek Instrument, Winooski, VT, USA). The IC 50 values for the HDAC assay were determined by plotting the fluorescence versus drug concentration. The compound concentration corresponding to 50% of the control is defined as the IC 50 value for the HDAC enzyme assay.
Determination of the acetylated proteins and Western blot analysis. HeLa cells cultured in 60-mm dishes under the conditions already described were treated with drugs for 8 h. After incubation, the cells were treated with a lysis buffer containing 0.5% TritonX-100 in a phosphate buffer at pH 8.0, and lysates were prepared by centrifugation at 13,000 rpm for 10 min. A Western blot analysis was performed as previously described. 26) Briefly, the HeLa cell lysate was electrophoresed by 15% polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a PVDF membrane (Millipore, Bradford, MA, USA). The membrane was incubated with the antibody against acetylated histone or acetylated/non-acetylated tubulin, and subsequently with the -rabbit or -mouse antibody. The level of acetylated proteins was detected with an enhanced chemiluminescence reagent (NEL105, Perkin Elmer) using X-ray film.
RT-PCR analysis. HeLa cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS) and maintained in a humidified incubator adjusted with 5% CO 2 . The cells were treated with the compounds for 24 h, and total RNA was prepared. The synthesis of cDNA and standard PCR were performed as described previously.
26) The primer pairs used for RT-PCR were the following: Wound healing assay. HeLa cells were seeded on a 12-well culture plate and incubated overnight. The cells grown in a monolayer were scraped off with a P200 pipette tip, washed with PBS, and incubated for 12 h in the presence and absence of several drugs. The timecourse characteristics for migration of the cells into the wound were observed by phase contrast microscopy. Photographic images were obtained immediately after scraping and after 6 h in the same locations. A quantitative analysis was presented by counting cells migrating from the scraped line.
In vitro invasion assay. The invasiveness of bovine endothelial cells (1 Â 10 5 cells per well) was performed in vitro by using a Transwell chamber with 8.0-mmpore-polycarbonate filter inserts (Corning Coster, Cambridge, MA, USA). The lower side of the filter was coated with 10 ml of gelatin (1 mg/ml), whereas the upper side was coated with 10 ml of Matrigel (Collaborative Biomedical Products, Bedford, MA, USA). The chamber was then incubated at 37 C for 18 h. The cells were fixed with MeOH and stained with hematoxylin/ eosin. Cell invasion was determined by counting the number of whole cells on the lower side of the filter, using optical microscopy at a Â100 magnification.
Band shift assay of IMPDH. K562 cells (1:8{2 Â 10 6 ) were pre-incubated in the presence or absence of 50 mM guanosine in 1 ml of a medium for 10 min. Pure DMSO or DMSO plus 1 or 2 was added, and the cells were cultured at 37 C for 1 h. The treated cells were collected by centrifugation for 3 min at 3,600 rpm, and lysed by sonication in 200 ml of a lysis buffer (20 mM Tris-HCl at pH 7.5, 1% SDS, 1% Triton X-100, 0.5% deoxycholate, 10% glycerol, 137 mM NaCl, 5 mM EDTA, 50 mM -glycerophosphate, 2 mM orthovanadate, 20 mM NaF, 1 mM DTT, 0.5 mM benzamidine, 10 mg/ml of leupeptin, and 10 mg/ml of aprotinin). Extracts were prepared by centrifugation at 13,000 rpm for 15 min.
Each sample was separated by 10% SDS-PAGE and transferred to a nitrocellulose membrane (Amersham Pharmacia Biotech, USA). IMPDH was monitored by -IMPDH antibodies and subsequent HRP-conjugated secondary antibodies.
Results and Discussion
Conversion of 1 into its hydroxamic acid derivative (2) was achieved by coupling activated MPA with hydroxylamine ( Table 1 ). The yields of 2 via acid chloride and subsequent treatment with hydroxylamine hydrochloride in the presence of Et 3 N (entries 1 and 2) were 10% and 19%, whereas that via mixed anhydride (entry 3) was improved to 38% (61% calculated yield based on the recovered starting material). MPHA (2) inhibited the enzymatic activity of HDAC at 1 mM in vitro (Table 2) .
To improve the biological features of 2 and the yields of the hydroxamic acid derivatives, we attempted the synthesis of MPHA analogs modified at 7-OH. These compounds, 3, 4, 11, 12 and 13, were obtained in high yields from the corresponding 7-O-functional MPA analogs (Table 1 , entries 5-9). Compounds 6, 8, 9 and 10 used as starting materials were prepared by previously described methods. 6) 7-O-Lauroyl MPA (7) was synthesized in 90% yield by the esterification of 1 with lauric acid anhydride. Conversion of 7 into its hydroxamic acid analog was achieved in 94% yield under the conditions described in the literature 27) (Table 1 , entry 6).
The effects of 1 and its hydroxamic acid analogs on the in vitro HDAC activity and cell proliferation were investigated as described in the Materials and Methods section. MPA (1) did not show any HDAC inhibitory activity, unlike its hydroxamic acid 2 and the 7-Ofunctionalized MPHA derivatives. Among the latter, compound 4 bearing a lauroyloxy group at C-7 was the most active compound in vitro (Table 2) . Although the differences in inhibitory activity among compounds 2, 3 and 4 were not significant, the 7-O-functionalized MPHA derivatives could be put in the following order of their decreasing activity: 4 > 3 ¼ 11 > 2 > 13 ) 12. In the antiproliferative test, compound 4 was again the most active. Its activity was two-fold higher than that of 1, 2 and the positive control, SAHA (Table 2) . Hydroxamic acid derivative 3, having an acetylated 7-OH group, showed an intermediate IC 50 value between that of 4 and those of 1 and 2. Substituting the 7-OH group with 7-OMEM or 7-OTs in the molecule of 2 resulted in decreased inhibitory activity against cell proliferation. These results suggested that only 2, 3 and 4 could be considered as candidates for therapeutic application as HDAC inhibitors. We therefore concentrated on further clarification of their biological features. It is already known that the inhibition of HDAC activity by specific inhibitors induces hyperacetylation of histones in drug-treated cells. Furthermore, HDAC inhibitors targeting HDAC6, which is involved in the stability of dynamic microtubules through tubulin acetylation regulation, induce the hyperacetylation of tubulin. 22) Although MPA did not induce the hyperacetylation of histone or tubulin in HeLa cells (data not shown), hydroxamic-acid analogs 2, 3 and 4 specifically induced hyperacetylation of tubulin (Fig. 2) . SAHA induced hyperacetylation of both histone and tubulin, whereas FK228, a known histone-specific HDAC inhibitor, selectively induced hyperacetylation of histone. 22) Notably, 2, 3 and 4 selectively induced hyperacetylation of tubulin and dose-dependently, implying that these analogs are new tubulin-specific HDAC inhibitors. These data also indicated that, unlike the antiproliferative effect of 1, those of 2, 3 and 4 might be dependant on the HDAC inhibitory activity specific for tubulin.
The expression level of target genes of HDAC was evaluated in the cells in order to validate the effects of 2, 3 and 4 on HDAC activity at the cellular level. A high concentration of 2 (10-20 mM) efficiently up-regulated the target genes of HDAC such as gelsolin and plakoglobin. Unlike the expression pattern from SAHA, 2 showed its effects relatively early after 6 h, with a gradual decrease of activity after 12 h (data not shown). These results suggested that 2 would be an effective HDAC inhibitor, gradually converting into its metabolites similarly to the case of mycophenolate mofetil. 28) This might be the reason why the IC 50 value of 2 against cell proliferation was level with that of 1. Low concentrations of 2, 3 and 4 (0.2-2 mM) did not upregulate target genes, similarly to tubacin (an -tubulinspecific inhibitor) and contrary to SAHA and histacin 22) (an -histone-specific HDAC inhibitor) (Fig. 3) . These observations demonstrated again that 2, 3 and 4 could be tubulin-specific HDAC inhibitors.
The regulation of tubulin-specific HDAC has been reported to control cell motility, 29) implying that an MPHA treatment and the resulting change in tubulin polymerization might serve to prohibit the migratory phenotype of the cells. To determine whether novel tubulin-specific inhibitors could prevent cell motility, a wound-healing assay was performed. Compounds 2, 3, 4 and tubacin potently inhibited the migration of tumor cells, whereas 11, 12 and 13 did not show any inhibition at 2 mM (Fig. 4) . The inhibitory effectiveness of these drugs decreased in the following order: 4 > 3 > 2 > tubacin ) 13 > 12 > 11.
Next, to evaluate the effect of most potent inhibitor 4 on growth factor-induced endothelial cell invasion, an in vitro invasion assay was conducted. Given the fact that metastasis and angiogenesis are dependent on cell movement, hyperacetylated tubulin induced by HDAC inhibitors may be responsible for the anti-metastatic and anti-angiogenic activities of HDAC inhibitors. 30) The invasion of bovine aortic endothelial cells (BAECs) was strongly induced by treatment with the vascular endothelial growth factor (VEGF), but 4 potently inhibited the BAEC invasion at a concentration of 2 mM with no cytotoxicity (Fig. 5) . Tubacin was used as a positive control for verifying the inhibition of HDAC6 activity in the cells. These data demonstrated that 4 and the derivatives altered the migration of cells by inhibiting the tubulin-specific HDAC activity, leading to suppression of the growth factor-induced endothelial cell invasion.
IMPDH catalyzes in several transition states: in the first step, a xanthosine 5 0 -monophosphate (XMP)-IMPDH intermediate and NADH are produced from IMP and NAD in a redox reaction, and in the second, NADH is released and the NAD-binding site is closed by the conformational change of IMPDH. In the third step, a hydrolysis reaction releases XMP. MPA and similar inhibitors can bind to the NAD-binding site, and inhibit conformational change in the second step. Therefore, the inhibition efficacy of MPA and its derivatives at the cellular level can be monitored as a mobility shift of IMPDH on SDS-polyacrylamide gel. [31] [32] [33] Here, we tested the effect of 2 on IMPDH in cultured cells with an immunoblotting analysis. A band shift of IMPDH appeared in the presence of 2 mM of 1 (Fig. 6, lane 2) . Incubation with 50 mM guanosine, which restores the guanine nucleotide pool through the hypoxianthine-guanine phosphoribosyl transferase (HGPRT) salvage pathway, partially prevented this band shift (Fig. 6, lane 4) . In contrast, the addition of 2 at 10 mM did not exhibit any band shift (Fig. 6, lane 3) . This The effects of drugs on the migrating ability of HeLa cells were evaluated by using wound-healing assay. The cells were incubated with drugs for 6 h. a, 0 h; b, control; c, 2 mM tubacin; d, 2 mM 2; e, 2 mM 3; f, 2 mM 4; g, 2 mM 11; h, 2 mM 12; i, 2 mM 13. The invasiveness of bovine endothelial cells was evaluated in vitro by using a Transwell chamber with 8.0-mm-pore-polycarbonate filter inserts. The lower side of the filter was coated with 10 ml of gelatin (1 mg/ml), whereas the upper side was coated with 10 ml of Matrigel. BAEC (1 Â 10 5 cells) was plated in the upper part of the filter. The chamber was then incubated at 37 C for 18 h. The cells were fixed with MeOH and stained with hematoxylin/eosin. a, no serum; b, VEGF; c, 2 mM tubacin; d, 2 mM 4. result suggests that the conversion of 1 into its hydroxamic acid caused the reduction of IMPDH inhibitory activity, 33) and that such hydroxamic acid derivatives as 2, 3 and 4 are selective inhibitors of tubulin deacetylase (HDAC6, or TDAC belongs to class II HDACs) 29, 34) at the cellular level. We therefore succeeded in converting the primary target of MPA from IMPDH to HDAC6 in the cells by a simple and efficient transformation of 1 into hydroxamic acid analogs 2, 3 and 4. The inhibitory activity of 2 against a nuclear extract of HDACs was 10-fold less potent than SAHA, similar to the result reported by Pankiewicz et al.
25) The effectiveness of 2, 3 and 4 as HDAC inhibitors at the cellular level was higher than that of the known tubulin-specific HDAC inhibitor, tubacin. Pankiewicz et al. have also reported the Ki values for MPA toward IMPDH (0.04 mM for type I; 0.01 mM for type II) and 2 (0.07 mM for type I; 0.03 mM for type II). 25) Our cell level assay toward IMPDH, which is well recognized as a reliable index for the inhibition of MPA against IMPDH 33) shows that the inhibitory effect of 2 was around 10-fold lower than that of MPA. This is a new example showing that the conversion of MPA leads to its improved biological properties. A number of therapeutic agents with the MPA pharmacophore has been developed and used for treating autoimmune disorders. 35) Furthermore, a drug with a hydroxamic acid function (SAHA) has been approved for treating cutaneous T cell lymphoma. 36) Our results therefore show that the transformation of 1 into such hydroxamic acid analogs as 2, 3 and 4 seems to offer good prospects in the fight against cancer.
